Patients and behavioral scientists call for single, simple PAL phrase and major education push

Speakers representing patient groups and behavioral science teams told FDA that current precautionary allergen labeling (PAL) is inconsistent and widely misunderstood. Ruchi Gupta (clinical researcher) presented survey and experimental data showing that many consumers do not know PAL is voluntary or tied to a specific quantity, and that different phrasings produce markedly different consumer behavior.

Carolyn Moisesi and advocacy organizations said their communities want a single, clear statement (for example, a standardized 'may contain' message) placed consistently on labels, paired with an education campaign and clinician outreach. FDA behavioral researchers said they will run focus groups to test label language and consumer comprehension and emphasized that some statements are interpreted as warnings while others are not.

Clinicians on the panels cautioned that thresholds alone will not reassure everyone: allergist speakers noted wide individual variability in sensitivity, limited access to specialists for many patients, and the need for shared decision-making. Speakers suggested clinical tools such as one-shot observed challenges or basophil activation testing could help individuals interpret generalized thresholds, but emphasized these approaches are not yet widely available.

Panelists agreed on four communication priorities: standardize PAL wording, test consumer comprehension with representative groups, coordinate an education campaign with patient organizations and clinicians, and develop materials and training for primary care providers and allergists so they can counsel patients on interpreting threshold-based labels.